Lung cancer is the leading cause of cancer-related death worldwide. The poor prognosis is partly due to lack of efficient methods for early diagnosis. MicroRNAs play roles in almost all aspects of cancer biology, and can be secreted into the circulation and serve as molecular biomarkers for the early diagnosis of cancer. In the present study, we determined the expression of miR-96 and the function of its target genes in lung cancer through bioinformatic analysis. Four microRNA expression profiles of lung cancer were downloaded from Gene Expression Omnibus and the data were analyzed using SPSS 16.0 software. Compared to the control group, expression of miR-96 was significantly increased in non-small cell lung cancer (NSCLC) (GSE51855), lung adenocarcinoma (GSE48414), stage I adenocarcinoma tissues (GSE63805) and the plasma of lung cancer patients (GSE68951). miR-96 was also elevated in six different NSCLC cell lines. However, the expression level of miR-96 was not related to the age, gender, clinical stage and histological subtype of the NSCLC patients. GO analysis of 78 predicted target genes of miR-96 showed that 42 of the obtained GO terms are highly associated with specific cellular processes including response to stimulus, signaling pathway, cell division, cell communication, cell migration and calcium signaling. KEGG results indicated that the miR-96 targets are mainly involved in the GnRH signaling pathway, long-term potentiation and insulin signaling pathway. In conclusion, miR-96, functioning as an oncogene, may play an important role in the development and progression of lung cancer. miR-96 may have the potential to serve as a molecular biomarker for the early diagnosis of NSCLC.
Introduction
Based on GIOBALCAN, an estimated 1.8 million new lung cancer cases and 1.6 million deaths occurred in 2012. This makes lung cancer the leading cause of cancer-related death among males worldwide and females in developed countries (1) . The poor prognosis is attributed to the lack of efficient methods for early diagnosis and lack of successful treatment for metastasis. Since non-small cell lung cancer (NSCLC), which accounts for approximately 85% of all lung cancer cases, is not very sensitive to chemotherapy and/or radiation, surgery remains the treatment of choice. However, most newly diagnosed NSCLC patients cannot undergo surgery due to local invasion or distant metastasis. Therefore, it is particularly important to study the molecular mechanisms underlying NSCLC, which may provide novel molecular targets for the early diagnosis of lung cancer.
MicroRNAs (miRNAs) are a group of non-coding RNAs (~22 nucleotides) that can degrade target mRNA transcripts directly or suppress their translation through complete or partial complementarity recognizing the 3'UTR of target mRNAs (2) . miRNAs have been proven to play an important role in the post-transcriptional regulation of gene expression and are involved in almost all aspects of cancer biology such as tumor transformation, growth, angiogenesis and epithelialmesenchymal transition by inhibiting specific oncogenes or tumor-suppressor genes. Accumulating data indicate that miRNAs are present in body fluids including blood plasma and serum, urine, saliva and semen (3, 4) and circulating miRNA levels are more accurate than the protein-coding gene profiles in tumor typing (5) . Therefore, miRNAs are more likely to be novel molecular biomarkers in the screening and monitoring of cancer patients (6) .
In our previous study, we found that DAL-1 (differentially expressed in adenocarcinoma of the lung-1; also known as EPB41L3, 4.1B) has an important role in the invasion and metastasis of NSCLC (7) . By using microRNA.org, TargetScan and PicTar, we predicted four miRNAs, miR-26a, miR-26b, miR-96 and miR-223, that regulate DAL-1. Data from several studies previously showed that miR-223 does not only promote the invasion of lung cancer cells but also the metastasis of gastric cancer via targeting tumor suppressor DAL-1 (8, 9) . Our previous study demonstrated that both miR-26a and DAL-1 gene expression are decreased in NSCLC, and DAL-1 is not a real target gene of miR-26a (10) . Both miR-26b and miR-26a belong to the miR-26 family, and miR-26b has low expression levels in many types of cancer, such as epithelial ovarian (EOC) (11) , hepatocellular carcinoma (HCC) (12) , as well as colorectal cancer (13) . In this study, we chose miR-96 as our research target.
MicroRNA-96 (hsa-miR-96, miR-96), located on chromosome 7 (7q31~34), belongs to the miR-183 gene family, which is the first gene cluster to be reported in the development and function of ciliated ectodermal cells and organs and is essential for the development and function of animal sensory organs (14, 15) . With the growing interest in the miR-183 gene family, miR-96 has been detected to be highly expressed in various human tumors and involved in cancer development by regulating key genes in tumor cell division and apoptosis (16) (17) (18) . Although studies have shown that miR-96 is overexpressed in lung cancer (19, 20) , it still remains unclear whether miR-96 could be used for early diagnosis and how miR-96 affects the progression of lung cancer. Herein, we determined the expression of miR-96 and the function of its target genes in lung cancer through bioinformatic analysis, aiming to ascertain whether it is a potential molecular biomarker for the early diagnosis of NSCLC and to obtain clues for the pathogenesis of lung cancer.
Materials and methods
Affymetrix microarray. The microRNA expression profiles of lung cancer (GSE51855, GSE48414, GSE63805, GSE68951) were downloaded from Gene Expression Omnibus (http:// www.ncbi.nlm.nih.gov/geo/), which are based on the platform of Affymetrix Human Genome U133 Plus 2.0 Array.
Probe re-annotation. Four TEX texts (GPL7341, GPL16770, GPL18410, GPL16770) were downloaded from GEO public data platform, to find the probe number of the hsa-miR-96 gene in GSE51855, GSE48414, GSE63805, GSE68951, respectively.
Cell culture. The following cell lines were cultured individually in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA): human lung adenocarcinoma (A549, NCI-H1299 and pAa), human lung large cell carcinoma (NCI-H460), human lung squamous cell carcinoma (NCI-H520), human lung small cell carcinoma (NCI-H446), human lung giant-cell carcinoma (95D) and human bronchial epithelial (16HBE) cell lines. The medium was supplemented with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 mg/ml streptomycin (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA). Cells were maintained in 5% CO 2 at 37˚C.
Real-time quantitative PCR. Specific RT primers and TaqMan probe (American ABI Company) were used for quantitative detection of hsa-miR-96 (cat no. A25576) and reference gene U6 (cat no. 4426961). Total RNAs in cells were isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The RNA yield and the ratio of absorbance at 260 to 280 nm (A260/ A280 ratio) were determined with the NanoDrop 2000 spectrophotometer (NanoDrop Technologies, Montchanin, DE, USA). The cDNA synthesis and qRT-PCR were carried out using the TaqMan MicroRNA Reverse Transcription kit and TaqMan MicroRNA assays and TaqMan ® Universal Master Mix, No AmpErase ® UNG (all from ABI, USA), respectively, according to the manufacturer's protocol. qRT-PCR was carried out using Applied Biosystems ® 7500 real-time PCR systems (Applied Biosystems, Foster City, CA, USA). The experiment was repeated 3 times. The relative quantitative analysis was carried out using the ΔΔCt method and the control was used for normalization of miRNA expression.
Bioinformatic analysis of miR-96 target genes. The target genes of miR-96 were predicted using miRecords. The intersection prediction results from at least 6 miRNA target gene prediction databases were analyzed to reduce the false-positive rate. To explore the functional annotation and pathway enrichment of those predicted genes, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) database analyses were conducted using a Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 online analysis tool with P<0.05 as the significant threshold to obtain significant gene sets.
Statistical analysis. All data are presented as mean ± SD and statistical analyses were processed using SPSS 16.0 statistical software. Wilcoxon's rank-sum test was used to compare the expression of miR-96 between lung cancer and normal lung tissues/plasma in GSE51855, GSE48414 and GSE68951. Wilcoxon matched-pairs signed ranks sum test was used to analyzed the miR-96 expression in GSE63805. Wilcoxon's rank-sum test and Kruskal-Wallis test were conducted to analyze the correlation of miR-96 expression with the clinicopathological features in GSE48414 and GSE51855. Independent-sample t-test was conducted to evaluate the miR-96 expression in lung cancer cell lines and 16HBE cells. A P-value of <0.05 was considered statistically significant.
Results
Expression of miR-96 in lung cancer tissues, plasma and cell lines. We analyzed four microRNA expression profiling datasets to explore the expression pattern of miR-96 in the tissues and plasma of lung cancer patients. The result indicate that, compared with the normal lung tissues, miR-96 was significantly increased in NSCLC (GSE51855, Fig. 1A and Table I , P<0.001), lung adenocarcinoma (GSE48414, Fig. 1B and Table II , P<0.001) and stage I adenocarcinoma tissues (GSE63805, Fig. 1C and Table III , P<0.001). In addition, the expression level of miR-96 in the plasma (GSE68951) of the lung cancer patients was significantly higher compared to that of the non-cancer lung disease patients ( Fig. 1D and Table IV, P<0.05).
We subsequently examined the level of miR-96 in different types of lung cancer cell lines and bronchial epithelial 16HBE cells using qRT-PCR. As shown in Fig. 2 , the expression level of miR-96 was elevated in all the 6 NSCLC cell lines but downregulated in the small cell lung cancer NCI-H446 cells. The highest expression levels for miR-96 were found in squamous cell carcinoma NCI-H520, adenocarcinoma NCI-H1299 and pAa cells (P<0.001 for each). 
Correlation between miR-96 expression and clinicopathological features of NSCLC.
We then analyzed the correlation between miR-96 expression and the clinicopathological features of NSCLC to further explore the potential role of miR-96 in the development and progression of lung cancer. Our results showed that the expression level of miR-96 in the tumors was not related to the age (P=0.631), sex (P=0.678), clinical stage (P= 0.841) and histological subtype (P= 0.051) of the NSCLC patients (GSE48414 and GSE51855, Tables V and VI).
Bioinformation analysis of miR-96
Prediction of miR-96 targets. Next, we used miRecords database to investigate miR-96 targets. miRecords does not only provide the target gene prediction of miRNAs but also the exact target genes regulated by miRNAs, which have already been experimentally validated. As shown in Table VII , a total of 71 target genes of miR-96 were predicted by at least six prediction softwares involved in miRecords. Ten miR-96 target genes were found and experimentally validated in the miRecords database, among which ADCy6, IRS1 and MyRIP were also in the prediction list. Finally, 71 predicted and 7 validated miR-96 targets (Table VII) were involved in the GO and KEGG analysis.
Gene ontology and KEGG pathway enrichment analysis of miR-96 target genes. Gene ontology enrichment analysis was performed to analyze 78 miR-96 target genes (Table VII) . In total, 42 GO terms were obtained, which included 24 biological processes, 15 cellular components and 3 molecular functions. These 42 GO terms were sorted by P-values for further analysis and are listed in Tables VIII and IX. Among the 24 biological process GO terms, the top 10 terms were: GO:0009725 (response to hormone stimulus), GO:0009719 (response to endogenous stimulus), GO:0010033 (response to organic substance), GO:0016197 (endosome transport), GO:0032228 (regulation of synaptic transmission, GABAergic), GO:0016055 (Wnt receptor signaling pathway), GO:0032868 (response to insulin stimulus), GO:0044057 (regulation of system process), GO:0007169 (transmembrane receptor protein tyrosine kinase signaling pathway) and GO:0042325 (regulation of phosphorylation) (Table VIII) .
The 15 cellular component GO terms were: GO:0042995 (cell projection), GO:0005815 (microtubule organizing center), GO:0005624 (membrane fraction), GO:0005626 (insoluble fraction), GO:0031095 (platelet dense tubular network membrane), GO:0005813 (centrosome), GO:0031094 (platelet dense tubular network), GO:0000267 (cell fraction), GO:0044463 (cell projection part), GO:0045202 (synapse), GO:0012505 (endomembrane system), GO:0005955 (calcineurin complex), GO: 0044430 (cytoskeletal part), GO:0045121 (membrane raft) and GO:0005856 (cytoskeleton) ( Table IX) .
In regards to the molecular function of the GO terms, GO:0005220 (inositol 1,4, 5-trisphosphate-sensitive calcium-release channel activity), GO:0008095 (inositol-1,4,5trisphosphate receptor activity) and GO:0005516 (calmodulin binding) were the highest presented terms (Table X) .
KEGG pathway analysis indicated that miR-96 target genes are mainly enriched in 9 pathways (Table XI) . Among these pathways, hsa04912 (GnRH signaling pathway) ( Fig. 3 ), hsa04114 (oocyte meiosis), hsa04720 (long-term potentiation) ( Fig. 4 ), hsa04910 (insulin signaling pathway) ( Fig. 5 ), hsa05215 (prostate cancer) and hsa04540 (gap junction) showed significantly higher enrichment, followed by hsa04916 
Discussion
Owing to its elevated expression, much effort has been dedicated to study the role of miR-96 in various types of cancers (21) (22) (23) . In the majority of the tumors, miR-96 acts as an oncogene to promote the proliferation and invasion of cancer cells by inhibiting transcription factor FOXO1 (24), FOXO3a (25), tumor suppressor protein RECK (26) and metastasis suppressor protein MTSS1 (27) . However, in pancreatic cancer, miR-96 functions as a tumor suppressor by targeting HERG1 and NUAK1 (28, 29) .
There is no explicit conclusion whether miR-96 could affect the development and progression of lung cancer and serve as a molecular biomarker for the clinical diagnosis of lung cancer. By analyzing four microRNA expression profiles and qRT-PCR, we showed that miR-96 was markedly increased in NSCLC, lung adenocarcinoma, stage I adenocarcinoma tissues and NSCLC cell lines. Consistent with our result, Ma et al reported that miR-96 was significantly upregulated in six NSCLC tissues and its expression was then validated in an independent set of 35 pairs of tumors and their conducted several studies to assess the function of miRNAs in the sputum and plasma of lung cancer patients (30) . They showed that the expression profile of plasma miR-21, miR-126, miR-210 and miR-486-5p produce high sensitivity and specificity in identifying stage I NSCLC patients. Zhu et al examined 70 pairs of lung cancer and non-cancerous tissues as well as serum samples. They found that miR-96 expression in tumors was positively associated with its expression in serum (31) . Our data revealed that miR-96 expression in the plasma of lung cancer was significantly higher compared to that of non-cancer lung disease patients, suggesting that miR-96 may serve as a potential non-invasive marker for lung cancer diagnosis.
Although studies have shown that miR-96 is associated with poor overall survival in patients with pancreatic cancer (32), liver cancer (33) and colorectal cancer (34), our results did not demonstrate any significant correlation between the expression level of miR-96 and clinical stage as well as the histological subtype of the NSCLC patients. These discrepancies may be due to the different samples and databases that were used. Further studies are needed to confirm whether miR-96 could serve as a prognostic biomarker for lung cancer.
To date, computational methods have been widely used for the prediction of miRNAs and their target genes. However, the most commonly used miRNA target prediction websites, such as TargetScan, microRNA.org and PicTar, could not yield consistent results due to their different algorithm. miRecords is an integrated microRNA target database which includes a total of 11 established prediction programs. In this study, we selected the results predicted by at least six softwares in miRecords as the putative miR-96 target gene set and a collection of 78 predicted target genes were involved in GO/KEGG functional enrichment analysis. Since the GO hierarchy contains an added complexity by allowing terms to have multiple parents or ascendants, we used Fisher's exact 0.01 to reduce the redundancy in lists of enriched GO terms. Our data showed that among the 24 biological process GO terms obtained, the top 10 terms could be roughly grouped into several different categories including response to the stimulus (GO:0009725, GO:0009719, GO:0010033 and GO:0032868), signaling pathway (GO:0016055, GO:0032868, GO:0007169) and neurotransmission (GO:0032228). Tyrosine kinase signaling (GO:0007169) is currently known as the most successful molecular-targeted therapeutic approach for lung cancer (35) . The canonical Wnt signaling pathway (GO:0016055), is another important regulator of proliferation (36) and metastasis (37) of non-small lung cancer cells. In addition, the 15 cellular component GO terms were significantly enriched in various specific processes with high frequency, such as cell division (GO:0005815, GO:0005813), cell communication (GO:0042995, GO:0044463) and cell migration (GO:0042995, GO:0044463, GO:0044430, GO:0005856), indicating that miR-96 may function as a regulator for the motility, migration and invasion of tumor cells. Moreover, three highly enriched molecular function GO terms (GO: 0005220, GO:0008095, and GO:0005516) suggest a potential new role of miR-96 in regulating calcium signaling important for tumor cell proliferation, apoptosis and migration.
In the KEGG annotation, GnRH signaling pathway (hsa04912), oocyte meiosis (hsa04114), long-term potentiation (hsa04720), insulin signaling pathway (hsa04910) and prostate cancer (hsa05215) showed the highest enrichment. GnRH has been reported to participate in the self-renewal of A549derived lung cancer stem-like cells by upregulating the jNK signaling pathway (38) . Insulin, bound to insulin receptor, promotes cell proliferation through the RAS-RAF-MAP kinase signaling pathway and regulates cell survival process through (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway, playing an important role in the clinical treatment of NSCLC (39) . Long-term potentiation and prostate cancer pathway, related to transcription regulation, cancer cell survival and proliferation respectively, suggest the potential function for miR-96 in cancer growth.
Although DAL-1 was not in the list of the 78 targets, DAL-1 was predicted as the target gene of miR-96 by 5 predicted databases of miRecords: MirTarget2, PicTar, PITA, RNAhybird, and TargetScan/TargetScanS (data not shown). For future studies, comprehensive screening, confirmation experiments and further bioinformatic analysis using available web tools such as Ingenuity Pathway Analysis (IPA) and STRINGProtein-Protein Interaction Networks need to be carried out on the predicted targets to explore the novel regulatory mechanism of miR-96 in cancer metastasis.
In conclusion, our results showed that miR-96, functioning as an oncogene, may play an important role in the development and progression of lung cancer. Both in tissue and plasma, miR-96 may have the potential to serve as a molecular biomarker for the early diagnosis of NSCLC.
